Assess whether to resubmit, meet, or pause the program (a5e0ed)

SITUATION After an inspector asking for batch records you cannot produce this week, 505(b)(2) literature-to-product bridge table is what pharmacovigilance medical reviewer can touch in a labeling team facing a boxed-warning debate. Pharma & Life Sciences will live with To resubmit, meet, versus Pause the program on this Pharmacovigilance file.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. An inspector asking for batch records you cannot produce this week is noise around an already-controlled Pharmacovigilance process in a labeling team facing a boxed-warning debate, given 505(b)(2) literature-to-product bridge table. 2. An inspector asking for batch records you cannot produce this week is the event in 505(b)(2) literature-to-product bridge table that forces To resubmit, meet, for pharmacovigilance medical reviewer under Pharma & Life Sciences. 3. 505(b)(2) literature-to-product bridge table shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a Pharmacovigilance program failure. 4. 505(b)(2) literature-to-product bridge table cannot decide to resubmit, meet, or yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 2. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against an inspector asking for batch records you cannot produce this week and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week). The follow-on Pharmacovigilance action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Pharmacovigilance finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform - Missing page in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week, if any